Does racial concordance between HIV-positive patients and their physicians affect the time to receipt of protease inhibitors? Authors
Populations At Risk
Cite this article as: King, W.D., Wong, M.D., Shapiro, M.F. et al. J GEN INTERN MED (2004) 19: 1146. doi:10.1111/j.1525-1497.2004.30443.x Abstract BACKGROUND: Compared to whites, African Americans have been found to have greater morbidity and mortality from HIV, partly due to their lower use of effective antiretroviral therapy. Why racial disparities in antiretroviral use exist is not completely understood. We examined whether racial concordance (patients and providers having the same race) affects the time of receipt of protease inhibitors. METHODS: We analyzed data from a prospective, cohort study of a national probability sample of 1,241 adults receiving HIV care with linked data from 287 providers. We examined the association between patient-provider racial concordance and time from when the Food and Drug Administration approved the first protease inhibitor to the time when patients first received a protease inhibitor. RESULTS: In our unadjusted model, white patients received protease inhibitors much earlier than African-American patients (median 277 days compared to 439 days; P<.0001). Adjusting for patient characteristics only, African-American patients with white providers received protease inhibitors significantly later than African-American patients with African-American providers (median 461 days vs. 342 days respectively; P<.001) and white patients with white providers (median 461 vs. 353 days respectively; P=.002). In this model, no difference was found between African-American patients with African-American providers and white patients with white providers (342 vs. 353 days respectively; P>.20). Adjusting for patients’ trust in providers, as well as other patient and provider characteristics in subsequent models, did not account for these differences. CONCLUSION: Patient-provider racial concordance was associated with time to receipt of protease inhibitor therapy for persons with HIV. Racial concordance should be addressed in programs, policies, and future racial and ethnic health disparity research. Key words HIV African Americans quality of health care physician-patient relations
Support for this study was provided by a grant to Dr. Wong from the Universitywide AIDS Research program #ID02-LA-031. Dr. Cunningham also received partial support from the UCLA-Drew Project Export, National Institutes of Health, National Center on Minority Health and Health Disparities (P20-MD00148-01), and the UCLA Center for Health Improvement in Minority Elders/Resource Centers for Minority Aging Research, National Institutes of Health, National Institute of Aging (AG-02-004).
Dr. King was partially supported by the UCLA Robert Wood Johnson Clinical Scholars Program and the Minority AIDS Training Program of the Adult AIDS Clinical Trial Group. The HIV Cost and Services Utilization Study was conducted under cooperative agreement U-01HS08578 (M.F. Shapiro, PI; S.A. Bozzette, Co-PI) between RAND and the Agency for Health Research and Quality. Substantial additional funding for this cooperative agreement was provided by the Health Resources and Services Administration, the National Institute of Mental Health, the National Institute on Drug Abuse, and the National Institutes of Health Office of Research on Minority Health through the National Institute of Dental Research. Additional support was provided by The Robert Wood Johnson Foundation, Merck and Company, Inc., Glaxo-Wellcome, Inc., the National Institute on Aging, the Office of the Assistant Secretary for Planning and Evaluation in the U.S. Department of Health and Human Services, and the Mary and Irving Lazar Program in Health Services Research at UCLA.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Vol. 13. Atlanta, Ga; 2001:1–44.
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Supplemental Report: Deaths Among Persons with AIDS Through December 2000. Atlanta, Ga; 2002:1–22.
Asch SM, Gifford AL, Bozzette SA, et al. Underuse of primary
prophylaxis in the United States. J Acquir Immune Defic Syndr. 2001;28:340–4.
Bing EG, Kilbourne AM, Brooks RA, Lazarus EF, Senak M. Protease inhibitor use among a community sample of people with HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;20:474–80.
Crystal S, Sambamoorthi U, Moynihan PJ, McSpiritt E. Initiation and continuation of newer antiretroviral treatments among Medicaid recipients with AIDS. J Gen Intern Med. 2001;16:850–9.
Cunningham WE, Markson LE, Andersen RM, et al. Prevalence and predictors of highly active antiretroviral therapy use in patients with HIV infection in the United States. HCSUS Consortium. HIV Cost and Services Utilization. J Acquir Immune Defic Syndr. 2000;25:115–23.
Jeffe DB, Meredith KL, Mundy LM, Fraser VJ. Factors associated with HIV-infected patients’ recognition and use of HIV medications. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;19:350–60.
Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305–15.
Stone VE, Clarke J, Lovell J, et al. HIV/AIDS patients’ perspectives on adhering to regimens containing protease inhibitors. J Gen Intern Med. 1998;13:586–93.
Moore RD, Stanton D, Gopalan R, Chaisson RE. Racial differences in the use of drug therapy for HIV disease in an urban community. N Engl J Med. 1994;330:763–8.
Palacio H, Kahn JG, Richards TA, Morin SF. Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature. Public Health Rep. 2002;117:233–51; discussion 231–2.
Sambamoorthi U, Moynihan PJ, McSpiritt E, Crystal S. Use of protease inhibitors and non-nucleoside reverse transcriptase inhibitors among Medicaid beneficiaries with AIDS. Am J Public Health. 2001;91:1474–81.
Andersen R, Bozzette S, Shapiro M, et al. Access of vulnerable groups to antiretroviral therapy among persons in care for HIV disease in the United States. HCSUS Consortium. HIV Cost and Services Utilization Study. Health Serv Res. 2000;35:389–416.
Cooper-Patrick L, Gallo JJ, Gonzales JJ, et al. Race, gender, and partnership in the patient-physician relationship. JAMA. 1999;282:583–9.
Laveist TA, Nuru-Jeter A. Is doctor-patient race concordance associated with greater satisfaction with care? J Health Soc Behav. 2002;43:296–306.
Murray-Garcia JL, Selby JV, Schmittdiel J, Grumbach K, Quesenberry CP Jr. Racial and ethnic differences in a patient survey: patients’ values, ratings, and reports regarding physician primary care performance in a large health maintenance organization. Med Care. 2000;38:300–10.
Saha S, Komaromy M, Koepsell TD, Bindman ABRD. Patient-physician racial concordance and the perceived quality and use of health care. Arch Intern Med. 1999;159:997–1004.
LaVeist TA, Nuru-Jeter A, Jones KE. The association of doctor-patient race concordance with health services utilization. J Public Health Policy. 2003;24:312–23.
Bozzette SA, Berry SH, Duan N, et al. The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. N Engl J Med. 1998;339:1897–904.
Frankel MR, Shapiro MF, Duan N, et al. National probability samples in studies of low-prevalence diseases. Part II: Designing and implementing the HIV cost and services utilization study sample. Health Serv Res. 1999;34(5 pt 1):969–92.
Mathews WC, McCutchan JA, Asch S, et al. National estimates of HIV-related symptom prevalence from the HIV Cost and Services Utilization Study. Med Care. 2000;38:750–62.
Rost K, Burnam MA, Smith GR. Development of screeners for depressive disorders and substance disorder history. Med Care. 1993;31:189–200.
Cunningham WE, Andersen RM, Katz MH, et al. The impact of competing subsistence needs and barriers on access to medical care for persons with human immunodeficiency virus receiving care in the United States. Med Care. 1999;37:1270–81.
Wilson IB, Ding L, Hays RD, Shapiro MF, Bozzette SA, Cleary PD. HIV patients’ experiences with inpatient and outpatient care: results of a national survey. Med Care. 2002;40:1149–60.
Kao AC, Green DC, Davis NA, Koplan JP, Cleary PD. Patients’ trust in their physicians: effects of choice, continuity, and payment method. J Gen Intern Med. 1998;13:681–6.
Landon BE, Wilson IB, Wenger NS, et al. Specialty training and specialization among physicians who treat HIV/AIDS in the United States. J Gen Intern Med. 2002;17:12–22.
Davison AC, Hinkley DV. Bootstrap Methods and Their Application. Cambridge, UK: Cambridge University Press; 1997.
Easterbrook PJ, Keruly JC, Creagh-Kirk T, et al. Racial and ethnic differences in outcome in zidovudine-treated patients with advanced HIV disease. Zidovudine Epidemiology Study Group. Jama. 1991;266:2713–18.
Lee LM, Karon JM, Selik R, Neal JJ, Fleming PL. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984–1997. JAMA. 2001;285:1308–15.
LaVeist TA, Carroll T. Race of physician and satisfaction with care among African-American patients. J Natl Med Assoc. 2002;94:937–43.
Chen J, Rathore SS, Radford MJ, Wang Y, Krumholz HM. Racial differences in the use of cardiac catheterization after acute myocardial infarction. N Engl J Med. 2001;344:1443–9.
Cooper LA, Roter DL, Johnson RL, Ford DE, Steinwachs DM, Powe NR. Patient-centered communication, ratings of care, and concordance of patient and physician race. Ann Intern Med. 2003;139:907–15.
van Ryn M, Burke J. The effect of patient race and socio-economic status on physicians’ perceptions of patients. Soc Sci Med. 2000;50:813–28.
Bogart LM, Catz SL, Kelly JA, Benotsch EG. Factors influencing physicians’ judgments of adherence and treatment decisions for patients with HIV disease. Med Decis Making. 2001;21:28–36.
Wong MD, Cunningham WE, Shapiro MF, et al. Disparities in HIV treatment and physician attitudes about delaying protease inhibitors for nonadherent patients. J Gen Intern Med. 2004;19:366–74.
Korthuis PT, Asch S, Mancewicz M, et al. Measuring medication: do interviews agree with medical record and pharmacy data? Med Care. 2002;40:1270–82.
Stein JH. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis. 2003;45:293–304.
Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450–1.
Report of the NIH Panel to Define Principles of Therapy of HIV Infection. Ann Intern Med. 1998;128:1057–8.
Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA. 1996;276:146–54.
Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection. Concorde Coordinating Committee. Lancet. 1994;343:871–81.
Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med. 1995;333:401–7.
Rabinowitz HK, Diamond JJ, Veloski JJ, Gayle JA. The impact of multiple predictors on generalist physicians’ care of underserved populations. Am J Public Health 2000;90:1225–8.
Carlisle DM, Gardner JE, Liu H. The entry of underrepresented minority students into U.S. medical schools: an evaluation of recent trends. Am J Public Health. 1998;88:1314–8.
Cohen JJ. Statistics don’t lie: anti-affirmative action is bad for our health. Acad Med. 1997;72:1084.
DeVille K. Defending diversity: affirmative action and medical education. Am J Public Health. 1999;89:1256–61.
PubMed CrossRef Copyright information
© Society of General Internal Medicine 2004